Australian biotech market today 17.03.09
Tuesday, 17 March, 2009
The pharma and biotech sector has gained a little in the share market at 2pm today, along with a small rise in the All Ordinaries, which is up 2 per cent.
Avexa (ASX:AVX) has continued its climb from yesterday and is now trading at 13c, almost doubling its value from last week. The company announced good results from its HIV drug trial yesterday.
Cochlear (ASX:COH) has also continued its upwards movement from yesterday, trading at a round $50. CSL (ASX:CSL) is yo-yoing again, as is Resmed (ASX:RMD).
Acrux (ASX:ACR), which last week announced the completion of enrolment in its Phase III trial of Axiron, a transdermal treatment for testosterone deficiency, is up 3c or 7.8 per cent. Circadian (ASX:CIR) is up 8c to 68.
API (ASX:API) is up slightly, as is Healthscope (ASX:HSP), now trading at a healthy $4.
BioMD (ASX:BOD) is up a cent, or almost 30 per cent of its value. Peplin (ASX:PLI), which is in Phase III with its lead candidate PEP005, is up 2c to 59c.
Bone Medical (ASX:BNE)is down 20 per cent, while Clinuvel (ASX:CUV) is down slightly. pSivida (ASX:PVA) is down 10c to $1, despite last week’s gains.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
